Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Jun
7
2014
Dietary Supplement Health and Education Act (DSHEA) – 20 Years Later – The Good, The Bad And The Ugly Sills Cummis & Gross P.C.
Jul
9
2019
Merck Sharp & Dohme Corp. v. Albrecht: The U.S. Supreme Court Weighs In On Preemption Sills Cummis & Gross P.C.
Apr
5
2023
D’Addario v. Johnson & Johnson – New Jersey Federal Court Addresses Express Pre-Emption In Class III Medical Device Case Sills Cummis & Gross P.C.
Nov
30
2018
In re Accutane Litigation: A Victory for Pharmaceutical Companies on Choice of Law and Label Warnings Sills Cummis & Gross P.C.
Aug
8
2014
Medical Devices: Parallel Claims Against Device Manufacturers post-Riegel? Sills Cummis & Gross P.C.
Jul
25
2019
Weeding through the NJ Medical Marijuana Law Amendments: What You Need to Know Sills Cummis & Gross P.C.
Apr
21
2021
New Jersey Appellate Division Finds that Evidence of 510(k) Clearance Cannot be Categorically Excluded in Medical Device Product Liability Cases Sills Cummis & Gross P.C.
May
2
2020
Re-Imagining the Shopping Center Post-COVID: Zoning Changes Needed to Accommodate Store Features No Longer Deemed Convenience Amenities Sills Cummis & Gross P.C.
Mar
4
2020
Federal Preemption in the Wake of Albrecht: The U.S. Supreme Court Unexpectedly Levels the Playing Field Sills Cummis & Gross P.C.
Feb
25
2021
New Jersey Cannabis Legalization Imposes New Burdens on Employers Sills Cummis & Gross P.C.
Feb
4
2020
Will the Coronavirus Make Your Business Sick? Much Shelist, P.C.
Apr
20
2020
DEA Provides Three Exceptions to Key Regulations Addressing the Treatment of Controlled Substances at Hospitals and Clinics Much Shelist, P.C.
Aug
22
2013
Coming Clean: EPA Finally Adopts Industrial Wipes Standard Much Shelist, P.C.
Apr
20
2020
Pharmacists Authorized to Order and Administer COVID-19 Testing Much Shelist, P.C.
Mar
6
2018
Drug Testing an Employee Who Reports a Work-Related Accident? Special Rules Apply Much Shelist, P.C.
Apr
29
2020
Pharmacy Groups Request COVID-19 Testing Authority for California Pharmacists Much Shelist, P.C.
Dec
6
2017
DEA Relaxes Requirements for Use of Automated Dispensing Systems in Long-Term Care Facilities — Is Illinois Next? Much Shelist, P.C.
Mar
5
2019
2018 Farm Bill Legalizes Hemp, but Obstacles to Sale of CBD Products Remain Much Shelist, P.C.
Sep
16
2015
New Business Opportunities for Pharmacies: Do You Have the Required Licenses? Much Shelist, P.C.
Oct
8
2015
Medical Cannabis in Illinois: What Health Care Providers and Organizations Need to Know Much Shelist, P.C.
Oct
22
2015
Medical Cannabis in Illinois: What Employers Need to Know Much Shelist, P.C.
Jul
26
2010
Has the Time Come for "Total Recall" of Medical Products? Sheppard, Mullin, Richter & Hampton LLP
Jan
6
2011
Landmark Greenhouse Gas Cap-and-Trade Program Adopted in California Sheppard, Mullin, Richter & Hampton LLP
Oct
6
2011
California AB 32's Cap-And-Trade Program Developments Sheppard, Mullin, Richter & Hampton LLP
Sep
22
2021
Elijah E. Cummins Lower Drug Costs Now Act: The Long and Winding Road to Drug Pricing Reform Sheppard, Mullin, Richter & Hampton LLP
Nov
22
2021
FDA Joins Other Regulators in Focus on AI and Machine Learning Sheppard, Mullin, Richter & Hampton LLP
Mar
24
2022
HHS OIG Signs Off on Substance Use Recovery Incentive Program Sheppard, Mullin, Richter & Hampton LLP
Jul
12
2019
Regulating E-Cigarettes Remains “Top Priority” For FDA Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins